Organ for breathing air
POPULARITY
Categories
419 episodes with pulmonary
117 episodes with pulmonary
79 episodes with pulmonary
57 episodes with pulmonary
34 episodes with pulmonary
37 episodes with pulmonary
56 episodes with pulmonary
32 episodes with pulmonary
32 episodes with pulmonary
20 episodes with pulmonary
25 episodes with pulmonary
15 episodes with pulmonary
13 episodes with pulmonary
14 episodes with pulmonary
11 episodes with pulmonary
16 episodes with pulmonary
26 episodes with pulmonary
15 episodes with pulmonary
6 episodes with pulmonary
11 episodes with pulmonary
10 episodes with pulmonary
9 episodes with pulmonary
10 episodes with pulmonary
8 episodes with pulmonary
8 episodes with pulmonary
6 episodes with pulmonary
6 episodes with pulmonary
13 episodes with pulmonary
4 episodes with pulmonary
9 episodes with pulmonary
4 episodes with pulmonary
7 episodes with pulmonary
10 episodes with pulmonary
4 episodes with pulmonary
5 episodes with pulmonary
4 episodes with pulmonary
10 episodes with pulmonary
7 episodes with pulmonary
11 episodes with pulmonary
10 episodes with pulmonary
4 episodes with pulmonary
3 episodes with pulmonary
4 episodes with pulmonary
5 episodes with pulmonary
5 episodes with pulmonary
4 episodes with pulmonary
4 episodes with pulmonary
4 episodes with pulmonary
4 episodes with pulmonary
7 episodes with pulmonary
3 episodes with pulmonary
7 episodes with pulmonary
4 episodes with pulmonary
6 episodes with pulmonary
Listener discretion is advised. Thank you to Pulmonologist Nick Ghionni and host of the EmCrit Podcast, Dr. Scott Weingart for coming onto the podcast and talking about approaches to the assessment and management of the often vague and really sick patient with respiratory distress.
Guest: Yana Zemkova, MD How often are ICU patients conscious during intubation despite paralysis? Hear from Dr. Yana Zemkova as she discusses new findings on the incidence of awareness with paralysis and the urgent need for improved monitoring in critical care. Dr. Zemkova is Clinical Assistant Professor of Internal Medicine specializing in Pulmonary, Critical Care and Occupational Medicine at the University of Iowa, and she spoke about this topic at the 2025 CHEST Annual Meeting.
Guest: Sujith Cherian MD, FCCP, DAABIP Obesity impacts how the lungs function in a variety of ways, and understanding these impacts is essential for interpreting pulmonary function tests, identifying restrictive or obstructive patterns, and managing ventilation. Learn more with Dr. Sujith Cherian, who's an Associate Professor in the Divisions of Critical Care, Pulmonary, and Sleep Medicine at University of Texas Health-McGovern Medical School and the Director of Interventional Pulmonology and Pleural Diseases at Lyndon B. Johnson Hospital in Houston. He also spoke about this topic at the 2025 CHEST Annual Meeting.
In this episode, Dr. Sergio Zanotti discusses the administration of vasopressor agents through peripheral intravenous lines (or what we refer to as “peripheral vasopressors”). He is joined by Dr. Elizabeth Munroe, a practicing pulmonary/critical care physician and an Assistant Professor of Pulmonary and Critical Care at Intermountain Health in Salt Lake City, Utah. Her research interests include evidence-based resuscitation practices in early sepsis and septic shock, vasopressor administration practices, peripheral vasopressor use, and clinical trials, particularly novel, pragmatic clinical trial designs. Additional resources: Peripheral Vasopressor Use in Early Sepsis-Induced Hypotension. ES Munroe, et al. JAMA Network 2025: https://pubmed.ncbi.nlm.nih.gov/40864467/ Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension. Shapiro NI, et al. CLOVERS Trial. New Engl J of Med 2025: https://pubmed.ncbi.nlm.nih.gov/36688507/ Overview of Peripheral Vasopressor Use in an Academic Health System. D Shyu, et al. Ann Am Thorac Soc 2025: https://pubmed.ncbi.nlm.nih.gov/40126143/ Safety of peripheral intravenous administration of vasoactive medication. J Cardenas-Garcia, et al. J Hosp Med 2015: https://pubmed.ncbi.nlm.nih.gov/26014852/ Books mentioned in this episode: Ending Medical Reversal- Improving Outcomes, Saving Lives. By Vinayak K. Parsad, et al: https://bit.ly/4nhCNam
Guest: David Feller-Kopman, MD Cytology via thoracentesis remains the first-line approach for diagnosing malignant pleural effusion (MPE), yet its sensitivity is limited. leaving many patients undiagnosed or delayed in treatment. In this expert-led discussion, Dr. David Feller-Kopman explores the limitations of current diagnostic methods and the evolving role of biomarkers in enhancing both diagnostic accuracy and prognostic insight. Dr. Feller-Kopman is a Professor of Medicine at the Geisel School of Medicine at Dartmouth and the Chief of Pulmonary and Critical Care Medicine at Dartmouth-Hitchcock Medical Center, and he discussed this topic at the 2025 CHEST Annual Meeting.
How I Survived Meth Addiction, Lung Failure, and Found Purpose Anthony Carrasco was a meth addict by 15, and nearly dead by 35. Diagnosed with PH after years of drug use, his story spiraled from homelessness to hospice. But a double lung transplant and a deep surrender to recovery transformed everything. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @JNJInnovMed
Breathing is a hot topic and we wanted to start the conversation with Helen Vanderburg, a world champion synchronized swimmer, gym owner, international presenter and a woman who has possibly taught a greater variety of fitness modalities than anyone else we know. This conversation includes key ways to use breath to activate, balance, and restore the body and mind and provides practical examples for exploring and expanding the use of breath with your clients and classes.Moving Conversation Socials Brian's Book on Low Back Pain and Conditions: Back Exercise; Stabilize, Mobilize and Reduce Pain https://a.co/d/8IUb7L6 Email: movingconvos@gmail.com IG: @movingconvos FB: Moving Conversations Brian IG: @fit4lifedc FB: https://www.facebook.com/brianrichey/ Nora IG: nora.s.john.7 FB: https://www.facebook.com/nora.s.john.7
As medicine shifts toward race-neutral lung function interpretation, new challenges emerge in ensuring equitable access to care. Dr. Ajay Sheshadri explores how race-neutral spirometry may impact patient selection for lung resection surgery and hematopoietic cell transplantation. Dr. Sheshadri is an Associate Professor in the Department of Pulmonary Medicine at the University of Texas MD Anderson Cancer Center.
Race-based spirometry adjustments have long influenced pulmonary risk assessments, often underestimating disease severity in Black patients. Hear from Dr. Ajay Sheshadri as he examines the historical misuse of race in lung function testing, explores race-neutral modeling in surgical risk prediction, and highlights the need for data-driven, continuous risk assessment tools in caring for patients with non-small cell lung cancer. Dr. Sheshadri is an Associate Professor in the Department of Pulmonary Medicine at the University of Texas MD Anderson Cancer Center.
Step 1 QBank: step1.mehlmanmedical.comStep 2CK QBank: step2.mehlmanmedical.comStep 3 QBank: step3.mehlmanmedical.comIG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/
Step 1 QBank: step1.mehlmanmedical.comStep 2CK QBank: step2.mehlmanmedical.comStep 3 QBank: step3.mehlmanmedical.comIG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/
This content was funded by Boehringer Ingelheim, who had no influence or involvement in the development of the content. This material is intended for U.S. healthcare professionals. Pulmonary fibrosis remains one of the most challenging respiratory diseases – often underdiagnosed, undertreated, and misunderstood. In this AMJ podcast, Ayodeji Adegunsoye and Toby Maher share their expert perspectives on how the field is changing, how recent data are shaping clinical decision-making, and why holistic, patient-centered care is critical. Chapters: 03:02 – 15:34 – A Decade Without New Options 15:34 – 27:47 – Understanding the Latest Clinical Trial Data 27:47 – 39:28 – From Hesitancy to Action: Reaching the Community Clinician 39:28 – 54:10 – Psychosocial Support and Patient-Centered Care 54:10 – 01:02:07 – The Role of Primary Care in ILD Diagnosis 01:02:07 – 1:07:48 – Call to Action Speakers: Ayodeji Adegunsoye, MD, PhD – Assistant Professor of Medicine, Biological Sciences Division, University of Chicago, Illinois, USA Toby Maher, MD, PhD – Professor of Clinical Medicine, Keck School of Medicine, University of Southern California, USA
Dr. Stephanie Maximous chats with Dr. Timothy Rowe about his paper, "Impact of Simulation-Based Mastery Learning on Management of Massive Hemoptysis."
Treating Meth-Associated PAH Without Judgment Dr. Brandon Jakubowski takes us into the underrecognized world of stimulant-induced pulmonary arterial hypertension. From misdiagnoses to under-prescribing life-saving therapies, he lays out the systemic gaps and stigmas preventing patients from getting the care they need. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @JNJInnovMed @UTSWMedCenter
Learning how to perform procedures on patients is an important part of medical training, but how do programs decide what to teach? And how do they integrate the latest technology? Host Eddie Qian, MD, from Vanderbilt University Medical Center, talks to Meredith Pugh, MD, MSCI, and Kaele Leonard, MD, of Vanderbilt University Medical Center. Together, they discuss how they think about working with trainees and fellows when it comes to teaching important procedures.
Fluid overload is a common problem in critically ill patients. In this episode, Dr. Sergio Zanotti discuss recognizing and managing fluid overload in the ICU with guest Dr. Michael J. Connor, Jr., a practicing intensivist and nephrologist. Dr. Connor is a Professor and Senior Physician of Critical Care Medicine & Nephrology at the Divisions of Pulmonary, Allergy, Critical Care, and Sleep Medicine and Renal Medicine at Emory University School of Medicine. Additionally, he serves as the director of critical care nephrology at the Emory Critical Care Center at Grady Memorial Hospital. Additional resources European Society of Intensive Care Medicine Clinical Practice Guideline on fluid therapy in adult critically ill patients: Part 3- fluid removal at de-escalation phase. Intensive Care Med 2025: https://pubmed.ncbi.nlm.nih.gov/40828463/ Optimizing Fluid Therapy in the Critically Ill. International Fluid Academy website – 2025: https://www.fluidacademy.org/2025/01/17/optimising-fluid-therapy-in-the-critically-ill-introduction-to-7d/ Fluid overload in the ICU: evaluation and management. R. Claure-Del Granado and R. L. Mehta. BMC Nephrology 2016: https://pubmed.ncbi.nlm.nih.gov/27484681/ Books and music mentioned in this episode: Think Again: The Power of Knowing What You Don't Know. By Adam Grant: https://bit.ly/4gZvz9c RUSHMERE. By Mumford & Sons: https://bit.ly/473FzKc
Andrew Gabrielson is a pediatric urology fellow at Lurie Children's Hospital of Chicago. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.T. Gabrielson and C. Corwin. Occupational Health and Safety on the Chopping Block — What's at Stake? N Engl J Med 2025;393:1353-1355.
The Face of Addiction Isn't Who You Think It Is Once thought to be a West Coast issue, methamphetamine-associated pulmonary hypertension is now a nationwide and global crisis. Dr. Nicholas Kolaitis reveals how building trust with meth associated-PAH patients can lead to incredible turnarounds, including sobriety, trial participation, and successful transplant. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @JNJInnovMed #PHawareMD @UCSFHospitals @LungTxptMD
Host: Diego Maselli, MD, FCCP Guest: Stephanie Christenson, MD Despite triple inhaled therapy, many patients with chronic obstructive pulmonary disease (COPD) continue to experience frequent and severe exacerbations, leading to hospitalizations, symptom burden, and higher mortality risk. In this expert-led discussion, Drs. Diego Maselli and Stephanie Christenson personalized treatment approaches and the role of biologics in advanced COPD care. Dr. Maselli is a Professor of Medicine at the Long School of Medicine at UT Health San Antonio, and Dr. Christenson is an Associate Professor in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine and an attending physician on the Pulmonary Consult Service and in the Pulmonary Clinic at the University of California in San Francisco. This program is produced in partnership with the American College of Chest Physicians and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
Dr. Ratika Parkash, Deputy Editor of JACC Clinical Electrophysiology, discusses The Association Between Atrial Fibrillation Burden and Quality of Life in Patients Undergoing Pulmonary Vein Isolation: A Sub-study of the SHAM-PVI Trial.
The Elective Rotation: A Critical Care Hospital Pharmacy Podcast
Show notes at pharmacyjoe.com/episode1066. In this episode, I'll discuss empiric posaconazole to prevent influenza-associated pulmonary aspergillosis. The post 1066: Can Empiric Posaconazole Prevent Influenza-Associated Pulmonary Aspergillosis? appeared first on Pharmacy Joe.
We review the diagnosis, risk stratification, & management of acute pulmonary embolism in the ED. Hosts: Vivian Chiu, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Acute_Pulmonary_Embolism.mp3 Download Leave a Comment Tags: Pulmonary Show Notes Core Concepts and Initial Approach Definition: Obstruction of pulmonary arteries, usually from a DVT in the proximal lower extremity veins (iliac/femoral), but may be tumor, air, or fat emboli. Incidence & Mortality: 300,000–370,000 cases/year in the USA, with 60,000–100,000 deaths annually. Mantra: “Don't anchor on the obvious. Always risk stratify and resuscitate with precision.” Risk Factors: Broad, including older age, inherited thrombophilias, malignancy, recent surgery/trauma, travel, smoking, hormonal use, and pregnancy. Clinical Presentation and Risk Stratification Presentation: Highly variable, showing up as anything from subtle shortness of breath to collapse. Acute/Subacute: Dyspnea (most common), pleuritic chest pain, cough, hemoptysis, and syncope. Patients are likely tachycardic, tachypneic, hypoxemic on room air, and may have a low-grade fever. Chronic: Can mimic acute symptoms or be totally asymptomatic. Pulmonary Infarction Signs: Pleuritic pain, hemoptysis, and an effusion. High-Risk Red Flags: Signs of hypotension (systolic blood pressure < 90 mmHg for over 15 minutes),
En este episodio del ECCpodcast, exploramos el SCAPE, o “Sympathetic Crashing Acute Pulmonary Edema”. Este síndrome representa una forma dramática de edema agudo de pulmón mediado por un colapso súbito de la función cardiopulmonar, con un componente simpático dominante que desencadena una cascada crítica de deterioro. A lo largo del episodio, desglosamos la fisiopatología, el diagnóstico diferencial, el manejo clínico y las estrategias avanzadas de intervención para SCAPE. Este artículo resume y amplía los puntos clave discutidos, con la intención de ofrecerte un recurso educativo robusto, ya seas médico, paramédico, enfermero o profesional de atención crítica. ¿Qué es SCAPE? SCAPE (Sympathetic Crashing Acute Pulmonary Edema) se refiere a una forma de edema pulmonar agudo con características distintivas: Inicio súbito: El paciente suele estar previamente normotenso o hipertenso, sin antecedentes inmediatos de insuficiencia cardiaca congestiva descompensada. Activación simpática intensa: Elevaciones abruptas en la presión arterial y frecuencia cardíaca desencadenan un círculo vicioso de congestión pulmonar y deterioro ventilatorio. Hipoxia severa y ansiedad extrema: El paciente se presenta en franca angustia respiratoria, luchando por aire y con sensación inminente de muerte. Esta condición es potencialmente reversible con un tratamiento rápido y apropiado, lo cual contrasta con otras causas de edema pulmonar en pacientes con falla sistólica crónica. Fisiopatología de SCAPE: Una tormenta simpática SCAPE no es simplemente edema pulmonar. Es el resultado de una descarga adrenérgica descontrolada, en muchos casos precipitada por un evento hipertensivo agudo o crisis de ansiedad. Hipertensión severa repentina → aumento de la poscarga → disfunción ventricular izquierda transitoria. Esto causa congestión pulmonar aguda, en minutos, con extravasación de líquido en los alvéolos. El resultado: edema pulmonar con dificultad respiratoria extrema, hipoxia, y ansiedad severa. En lugar de una descompensación progresiva de insuficiencia cardíaca, aquí vemos una crisis hemodinámica inducida por una tormenta simpática, en pacientes que usualmente tienen una fracción de eyección normal. Presentación clínica: El paciente que “se estrella” frente a ti El paciente con SCAPE puede presentarse con: Disnea súbita y severa Sibilancias generalizadas (puede confundirse con un cuadro asmático) Presión arterial muy elevada, típicamente ≥180 mmHg sistólica Frecuencia respiratoria y cardíaca elevadas Sudoración profusa, ansiedad extrema Rales bilaterales hasta vértices Uso de músculos accesorios Saturación de O₂ marcadamente reducida Estos signos deben diferenciarse de otras causas de disnea aguda como EPOC, asma, TEP, síndrome ansioso o neumonía. Diagnóstico diferencial: ¿Es SCAPE o no? El diagnóstico de SCAPE es principalmente clínico. Algunos elementos clave para distinguirlo incluyen: Diagnóstico diferencial Diferenciador clave Asma No hay historia asmática, no hay respuesta a broncodilatadores EPOC No hay hipersecreción crónica ni patrón obstructivo previo TEP No suele haber hipertensión severa ni edema pulmonar radiológico Neumonía Inicio más insidioso, fiebre, consolidación localizada Ansiedad No explica rales ni saturación baja sostenida El hallazgo de rales bilaterales, taquicardia, hipertensión severa, y signos de hipoxia crítica, especialmente en ausencia de historia de ICC, apunta fuertemente a SCAPE. Tratamiento inmediato: Qué hacer en los primeros 5 minutos En SCAPE, cada minuto cuenta. El manejo temprano es vital para revertir el curso clínico. El tratamiento se enfoca en tres pilares fundamentales: 1. Ventilación no invasiva (VNI) inmediata Iniciar CPAP o BiPAP en cuanto se identifica el cuadro. CPAP de inicio: 10 cmH₂O Mejora la oxigenación, recluta alvéolos colapsados, y reduce la precarga. Reduce la necesidad de intubación orotraqueal. 2. Nitroglicerina en bolos y goteo No es una hipertensión “de fondo” — se trata de una crisis aguda. Bolos de nitroglicerina IV de 400-800 mcg cada 2-3 minutos son preferibles al goteo lento. Luego se inicia goteo continuo a dosis altas (100-200 mcg/min). Objetivo: reducir rápidamente la poscarga. 3. Evitar intubación temprana La intubación agrava el cuadro si no se ha optimizado primero la poscarga. El uso agresivo de VNI y vasodilatadores puede evitar la necesidad de intubación en la mayoría de los casos. ¿Y los diuréticos? Un error común es administrar furosemida o torasemida como primer paso. En SCAPE: El paciente no tiene sobrecarga de volumen, sino redistribución aguda de fluidos por hipertensión. El diurético puede empeorar la hipotensión posterior. Puede considerarse después de estabilizar la presión y la oxigenación, no antes. Rol del ultrasonido en SCAPE El ultrasonido pulmonar y cardíaco a pie de cama puede ser útil: Pulmonar: líneas B difusas bilaterales, indicativas de edema intersticial. Cardíaco: disfunción ventricular izquierda, cavidades no dilatadas (útil para diferenciar de ICC crónica). El uso del ecógrafo puede reforzar el diagnóstico clínico y guiar intervenciones tempranas. Perlas prácticas del ECCpodcast Durante el episodio, se destacan múltiples “perlas clínicas” útiles para el manejo operativo de SCAPE: La mayoría de los pacientes con SCAPE tienen FEVI normal: no son pacientes con ICC descompensada. La sibilancia no siempre es asma: los rales y sibilancias en SCAPE vienen de edema, no de broncoespasmo. La nitroglicerina en bolo es tu mejor aliada: no temas usar dosis elevadas bajo monitoreo. No pierdas tiempo con diuréticos ni con salbutamol en estos casos. Usa CPAP agresivamente desde el inicio. No intubes a menos que hayas fallado en revertir el cuadro con VNI + nitro. Contexto prehospitalario: ¿Qué puede hacer el paramédico? Desde la perspectiva de atención prehospitalaria: Iniciar CPAP tan pronto como se identifique el cuadro. Administrar nitroglicerina sublingual en dosis repetidas, si no se cuenta con acceso IV. Monitorear la presión constantemente. SCAPE requiere agresividad controlada, no intervención ciega. Notificar al hospital del cuadro clínico temprano para que se preparen con VNI e intervenciones avanzadas. Conclusiones del episodio SCAPE representa una emergencia hipertensiva de alta mortalidad si no se trata de forma rápida y dirigida. El abordaje debe ser: Rápido Guiado por la fisiopatología Alejado de viejos esquemas de manejo de ICC Centrado en VNI + nitroglicerina Recursos adicionales Algoritmo de manejo de SCAPE en formato PDF Infografía resumen de SCAPE para descargas clínicas Referencias a estudios y guías clínicas mencionadas
How Stigma Blocks Meth-PAH Treatment and How to Stop It Patients with methamphetamine-associated-PAH often arrive at clinics already carrying heavy shame. But shame shouldn't be part of their medical history. In this compelling episode, Dr. Peter Leary explains how stigma—from both society and providers—can delay life-saving care. Learn how a change in mindset, language, and compassion can transform outcomes for a neglected and growing patient population. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @uwepidemiology @JNJInnovMed
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Assessing Cardiac Flow Measurements Using a Noninvasive Photoplethysmography-Based Device Compared to Invasive Pulmonary Artery Catheter.
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Noninvasive Estimation of Pulmonary Vascular Resistance Using Right Ventricular Outflow Doppler Analysis.
The Hidden Epidemic: Meth and PHMeth-Associated PAH is on the rise across the United States, yet many patients are not receiving the treatment they need. Dr. Vinicio de Jesus Perez discusses the shifting demographics of meth users, the challenges of treating addiction in cardiopulmonary care, and the need for compassionate, stigma-free screening. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @PHatStanford @Viniciodjperez @JNJInnovMed
The unstoppable Jennifer Dunlea is an advocate, a fighter, and an all-around powerhouse. Born with Cystic Fibrosis, Jen has faced more medical battles than most people do in a lifetime, including surviving a rare cancer at just 23 years old. She's a two-time double lung transplant recipient, living with diabetes and gastroparesis, and still somehow finds the energy to raise her voice, and awareness, for the CF and transplant communities every single day. You might know her from social media, where she shares her journey with honesty, humor, and heart under the handle @jencantbreathe on TikTok, Instagram, YouTube, and Facebook.Trust me, you're going to be inspired by this conversation.To follow Jen: @jencantbreatheCOTA health fundraising campaign: https://cota.org/cotaforjenslungs/our-story/The Sick Chick Hour: https://open.spotify.com/show/7eegd1SwLueAnrxueC7VVeYoutube for Jen: https://youtube.com/@jencantbreathe?si=QXrvZniAYTwjmv2v Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en
Dr. John Kingrey exposes the rising crisis of meth-associated pulmonary hypertension, a condition spreading fast across the U.S. He challenges misconceptions, highlights urgent research, and stresses the need for compassion in treating both PAH and addiction. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @integrishealth @teamphhope @JNJInnovMed #phawareMD
Every day we take a break from the busy work day to catch our break and hang out with friends to talk about Sports, Entertainment and specifically CrossFit. Today marks the aniversary of 9/11 and at the time I thought we would move in a positive direction as a country, when the reality has been the country has become more divided and Hate is showing its head more than ever. Also as a Kid their were elite companies you would see and know they were the ones you wanted to be with if you got famous, do we have that in CrossFit now? and I fill you in on my pulmonary test from today.
Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.
Delays in diagnosing and treating pulmonary hypertension (PH) can have life-altering consequences. In this episode, Dr. Kari Gillmeyer, discusses her groundbreaking study on PH care networks. She explores why so many patients experience delays, how geography and provider access play a role, and what can be done to improve timeliness of care. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @VABostonHC @The_BMC @JNJInnovMed
A 200 Mile Journey from LA to San Diego to Raise Awareness for PH When Eric Borstein collapsed in his bedroom in 2020, doctors gave him just months to live. Instead, he fought back with walking, mental health, and the support of his community. Now, he's leading a movement, raising hundreds of thousands for pulmonary hypertension research, and walking 200 miles down the California coast to prove hope has no limits. Learn more about the 2nd Annual Where is EB? 5K Walk and Fundraiser September 7, 2025 Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com @teamphhope @where_is_eb @DJLisaFoxx
We break down pneumothorax: risks, diagnosis, and management pearls. Hosts: Christopher Pham, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Pneumothorax.mp3 Download Leave a Comment Tags: Chest Trauma, Pulmonary, Trauma Show Notes Risk Factors for Pneumothorax Secondary pneumothorax Trauma: rib fractures, blunt chest trauma (as in the case). Iatrogenic: central line placement, thoracentesis, pleural procedures. Primary spontaneous pneumothorax Young, tall, thin males (10–30 years). Connective tissue disorders: Marfan, Ehlers-Danlos. Underlying lung disease: COPD with bullae, interstitial lung disease, CF, TB, malignancy. Technically, anyone is at risk. Symptoms & Differential Diagnosis Typical PTX presentation: Dyspnea, chest pain, pleuritic discomfort. Exam clues: unilateral decreased breath sounds, focal tenderness/crepitus. Red flags (suggest tension PTX): JVD Tracheal deviation Hypotension, shock physiology Severe tachycardia, hypoxia Differential diagnoses: Pulmonary: asthma, COPD, pneumonia, pulmonary edema (SCAPE), ILD, infections. Cardiac: ACS, CHF, pericarditis. PE and other acute causes of dyspnea. Diagnostics Bloodwork: limited role, except type & screen if intervention likely. EKG: reasonable given chest pain/shortness of breath.
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Predictors of Length-of-Stay Among Transcatheter Aortic Valve Replacement Patients Using a Supervised Machine Learning Algorithm.
Send us a textThis week we have a physiology heavy hitter - we review cardiac hemodynamics and how to translate those principles into the use and application of PA catheters. Written by: Dr. Paul Mundra (Internal Medicine Resident) Reviewed by: Dr. Craig Ainsworth (Cardio-Intensivist) & Dr. Hugh Traquair (General Internist) Don't forget to use code FIGSCA for 20% off your first purchase! Support the show
In this episode, Dr. Akshay Muralidhar, Co-Director of the Pulmonary Hypertension Center of Excellence at Arizona Pulmonary Specialist in Phoenix, discusses the importance of having a specialized center for pulmonary hypertension. Dr. Muralidhar also highlights the challenges of managing patients with substance abuse issues, particularly methamphetamine use. Dr. Muralidhar emphasizes the importance of access to care, particularly for underserved communities, and the need for outreach programs to ensure that all patients have access to treatment options. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD @JNJInnovMed
UAB's adult ECMO program, which offers advanced heart and lung support, continues to expand in both reach and capability. Keith Willie, M.D., medical director of the ECMO and Advanced Lung Diseases Program, discusses technology that improves patient mobility, new referral partnerships, and the multidisciplinary care model behind each case. Learn how ECMO is used as a bridge to recovery, transplant, or decision. Learn more about Keith Wille, MD, MSPH
Dr. Raj Parikh from Hartford Hospital discusses building on foundational pathways with treatment options for Pulmonary Arterial Hypertension (PAH) patients. He also emphasizes the value of clinical trials as well as the importance of a good doctor/patient relationship. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD @HartfordHealthC @JNJInnovMed
Step 1 QBank: step1.mehlmanmedical.comStep 2CK QBank: step2.mehlmanmedical.comStep 3 QBank: step3.mehlmanmedical.comIG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/
In this episode, host Sandip Roy discusses India's national sleep crisis, a problem that affects all ages, from anxious teenagers to overworked professionals, with Dr. G.C. Khilnani, a renowned pulmonologist and chairman of the PSRI Institute of Pulmonary, Critical Care and Sleep Medicine, to understand why sleeplessness has become such a widespread concern.They discuss everything from sleep hygiene and circadian rhythm disruptions to insomnia, sleep apnea, and how modern lifestyles, screen addiction, and late-night habits are quietly eroding the quality of our sleep and our health.Produced by Shashank BhargavaEdited and mixed by Suresh Pawar
In this episode, we review the high-yield topic Inhaled Beta-Agonists from the Pulmonary section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Tom Frieden is the president and chief executive officer of Resolve to Save Lives and former director of the Centers for Disease Control and Prevention. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. T.R. Frieden. Dismantling Public Health Infrastructure, Endangering American Lives. N Engl J Med 2025;393:625-627.
In this episode, we review the high-yield topic Inhaled Muscarinic-Antagonists from the Pulmonary section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Dr. Robert Frantz breaks down the key metrics behind risk stratification—functional class, six-minute walk distance, and brain natriuretic peptide levels—and explains how they shape treatment plans. He also explores the role of echocardiography, right heart catheterization, and cutting-edge therapies in improving patient outcomes. Read the proceedings of the Task Force on Risk Stratification from the Seventh World Symposium on Pulmonary Hypertension. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on social @phaware Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com #phawareMD #RiskStratification @MayoClinic @MayoMedEd @TeamPHHope @JNJInnovMed
In this episode, we review the high-yield topic COPD Exacerbation from the Pulmonary section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Lung cancer, particularly non-small cell lung cancer (NSCLC), is the deadliest cancer worldwide. Cigarette smoking is one of the main causes, but not every smoker develops the disease. This suggests that other biological factors help determine who develops cancer. Researchers from the Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indianapolis, and from the Richard L. Roudebush Veterans Affairs Medical Center have now found that cigarette smoke, combined with a weakened DNA repair system, can trigger the early stages of lung cancer, particularly NSCLC. This work, led by first author Nawar Al Nasralla and corresponding author Catherine R. Sears, was recently published in Volume 16 of Oncotarget. Full blog - https://www.oncotarget.org/2025/08/11/cigarette-smoke-and-weak-dna-repair-a-double-hit-behind-lung-cancer-risk/ Paper DOI - https://doi.org/10.18632/oncotarget.28724 Correspondence to - Catherine R. Sears - crufatto@iu.edu Video short - https://www.youtube.com/watch?v=UEiCz834a8c Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28724 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, DNA repair, DNA damage, lung adenocarcinoma, squamous cell carcinoma, Xeroderma Pigmentosum Group C (XPC) To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
ICU & You: What Happens When Pulmonary Hypertension Turns Critical? Pulmonary hypertension is already a complex condition, but what happens when it becomes life-threatening? Dr. Jean Elwing breaks down what patients and families can expect when someone with PH ends up in the ICU. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD @uc_health @ElwingJean @accpchest
Watch the NEJM In Studio video of this interview at NEJM.org. Rohan Khazanchi is a research affiliate at the FXB Center for Health and Human Rights at Harvard University and a resident in the Harvard Medicine-Pediatrics Residency Program. Harleen Marwah, the interviewer, is a recent Editorial Fellow at the Journal. R. Khazanchi and Others. Reform and Remedy for Imprecision and Inequity — Ending the Race-Based Evaluation of Occupational Pulmonary Impairment. N Engl J Med 2025;393:508-514.
In today's episode, we connect with Dr. Aahd Kubbara to discuss the intricacies of lung function and targeted biological therapies for asthma. Dr. Kubbara is a practicing pulmonologist and intensivist at the University of Minnesota Medical Center, where he also serves as an Assistant Professor of Medicine, Pulmonary, Allergy, Critical Care, and Sleep and Associate Program Director of the Pulmonary and Critical Care Fellowship. Hit play to discover: The types of inflammatory diseases that can lead to lung scarring. The consequences of untreated asthma over years of time. What pulmonary fibrosis is, and how to treat it. The potential impacts of normalizing chronic health symptoms. How seasonal asthma is typically triggered and how to mitigate it. Dr. Kubbara brings a wealth of experience to his field, including a year in Critical Care at the Mayo Clinic in Rochester, and another year in Academic Pulmonary and Critical Care at the University of Nevada, Reno. He also spent a year practicing community Pulmonary and Critical Care at both Mayo Clinic Eau Claire and Aspirus Wausau Hospital. In addition, he completed an advanced fellowship in Interstitial Lung Disease and Vasculitis at the Mayo Clinic. To learn more about Dr. Kubbara and his work, click here! Episode also available on Apple Podcasts: http://apple.co/30PvU9C Keep up with Julian R. Gershon Jr. socials here: Instagram: https://www.instagram.com/aahd_kubbara/?hl=en X : https://x.com/aahdkubbara
© 2020-2025 Ivy Podcast Discovery LLC
